Chemo, radiation, and immunotherapy for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (PD-1 inhibitor) before surgery for locally advanced rectal cancer located below the peritoneal reflex. The goal is to see if this approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have rectal adenocarcinoma that is pMMR/MSS type.
- Your tumor is below the peritoneal reflex and has not spread to other organs.
- You have not had pelvic radiation, rectal cancer surgery, or chemotherapy before.
- Your heart, lung, liver, and kidney functions are adequate for surgery.
- You do not have active autoimmune disease, tuberculosis, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
This trial tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemoradiation and targeted therapy improves outcomes for locally advanced rectal cancer. It is for patients who have not had prior treatment and do not have certain genetic markers (BRAF mutation or MSI-H).
This trial tests whether adding radiation therapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (PD-1 antibody) is more effective than the combination alone for people with locally advanced rectal cancer that is MSS (microsatellite stable) or pMMR. It aims to improve outcomes for patients with high-risk features.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
Hear when a new Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.